Cambridge, UK, 22 May 2007 - Medical Marketing International Group plc (MMI) (AIM:MMG), the pharmaceutical company focused on the development of drugs for cancer and infectious disease, today announces that preliminary data from The University of Southampton Phase I/II prostate cancer trial, using a vaccine that incorporates the Genvax immunostimulant technology, will be presented by Dr Christian Ottensmeier at a major DNA vaccines conference being held in Malaga, Spain on 23-25 May.
